Allergan, Inc.

Patton E Garay

Kei Roger Aoki

Ester Fernandez-Salas

Joanne Wang

Lina Wong

D Dianne Hodges

D Diane Hodges

Birgitte P S Jacky

Fernandez-Salas Ester

Kei Rogers Aoki

Lina S Wong

The present specification discloses SNAP-25 compositions, methods of making &#x3b1;-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the Presidue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, &#x3b1;-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the Presidue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing &#x3b1;-BoNT/A antibodies.

Immuno-based botulinum toxin serotype A activity assays

Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to a FGFR2, a FGFR3, a SV2, or any combination thereof, to a governmental or regional regulatory authority.

Botulinum toxin screening assays

Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.

Growing community of inventors

Long Beach, CA, United States of America

Patton E Garay